Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Pauline A. Merle"'
Autor:
Corine J. Hess, Nicole Feller, Fedor Denkers, Angèle Kelder, Pauline A. Merle, Michael C. Heinrich, Amy Harlow, Johannes Berkhof, Gert J. Ossenkoppele, Quinten Waisfisz, Gerrit J. Schuurhuis
Publikováno v:
Haematologica, Vol 94, Iss 1 (2009)
Background About 70–80 percent of patients with acute myeloid leukemia enter complete remission, but at least half of these patients who achieve remission go on to relapse. Improved treatment is likely to come from increasing the time to relapse, e
Externí odkaz:
https://doaj.org/article/000a5dbd77e8473c871c7c8c45cc02f0
Autor:
François G. Kavelaars, Elvira Verhoef, Bianca Venniker-Punt, Peter J. M. Valk, Christian M. Vonk, Pauline A. Merle, Zinia J. Kwidama, Jacqueline Cloos, Patrycja L Gradowska, Jeroen Janssen, David G. J. Cucchi, Bob Löwenberg, Melissa Rijken
Publikováno v:
Cucchi, D G, Vonk, C M, Rijken, M, Kavelaars, F, Merle, P, Verhoef, E, Venniker-Punt, B, Kwidama, Z J, Gradowska, P, Löwenberg, B, Janssen, J J W M, Cloos, J & Valk, P J M 2021, ' DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia ', BLOOD ADVANCES, vol. 5, no. 21, pp. 4476-4479 . https://doi.org/10.1182/bloodadvances.2021004980
Blood Advances
Blood advances, 5(21), 4476-4479. American Society of Hematology
BLOOD ADVANCES, 5(21), 4476-4479. American Society of Hematology
Blood Advances
Blood advances, 5(21), 4476-4479. American Society of Hematology
BLOOD ADVANCES, 5(21), 4476-4479. American Society of Hematology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28b787f38dc96d2345cc2e518086b31a
https://research.vumc.nl/en/publications/0a7b0550-67cd-4a96-a66d-a7a25142ae3d
https://research.vumc.nl/en/publications/0a7b0550-67cd-4a96-a66d-a7a25142ae3d
Autor:
M. A. Veening, Shama L. Bhola, V. de Haas, J. W. Wessels, Marielle J. Wondergem, Pauline A. Merle, M. B. Mansur, Gertjan L. Kaspers, Pino J. Poddighe, W.A. Kors, A. M. Ford, Theresia M. Westers, A H Loonen
Publikováno v:
Human Pathology: Case Reports, Vol 11, Iss, Pp 34-38 (2018)
Poddighe, P J, Veening, M A, Mansur, M B, Loonen, A H, Westers, T M, Merle, P A, Wessels, J W, de Haas, V, Kors, W A, Bhola, S L, Wondergem, M J, Ford, A M & Kaspers, G J L 2018, ' A novel cryptic CBFB-MYH11 gene fusion present at birth leading to acute myeloid leukemia and allowing molecular monitoring for minimal residual disease ', Human Pathology: Case Reports, vol. 11, pp. 34-38 . https://doi.org/10.1016/j.ehpc.2017.09.001
Human Pathology: Case Reports, 11, 34-38. Elsevier Inc.
Poddighe, P J, Veening, M A, Mansur, M B, Loonen, A H, Westers, T M, Merle, P A, Wessels, J W, de Haas, V, Kors, W A, Bhola, S L, Wondergem, M J, Ford, A M & Kaspers, G J L 2018, ' A novel cryptic CBFB-MYH11 gene fusion present at birth leading to acute myeloid leukemia and allowing molecular monitoring for minimal residual disease ', Human Pathology: Case Reports, vol. 11, pp. 34-38 . https://doi.org/10.1016/j.ehpc.2017.09.001
Human Pathology: Case Reports, 11, 34-38. Elsevier Inc.
Acute myeloid leukemia (AML) with the inv(16)/t(16;16) karyotype is associated with a favourable prognosis, showing longer periods of complete remission and high overall survival rates. Here we report a four year old girl, who presented with pallor,
Autor:
Arjo P Rutten, Fedor Denkers, Pino J. Poddighe, Han J.M.P. Verhagen, Marjon A. Smit, Pauline A. Merle, Gert J. Ossenkoppele, Linda Smit
Publikováno v:
Blood, 127(4), 458-463. American Society of Hematology
Verhagen, H J M P, Smit, M A, Rutten, A, Denkers, F, Poddighe, P J, Merle, P A, Ossenkoppele, G J & Smit, L 2016, ' Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid ', Blood, vol. 127, no. 4, pp. 458-463 . https://doi.org/10.1182/blood-2015-07-653840
Verhagen, H J M P, Smit, M A, Rutten, A, Denkers, F, Poddighe, P J, Merle, P A, Ossenkoppele, G J & Smit, L 2016, ' Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid ', Blood, vol. 127, no. 4, pp. 458-463 . https://doi.org/10.1182/blood-2015-07-653840
Enhanced expression of ecotropic viral integration site 1 (EVI-1) occurs in ∼10% of acute myeloid leukemia (AML) patients and is associated with a very poor disease outcome. Patients with EVI-1-positive AML have poor initial responses to chemothera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2a0e98aab0606e23f4094e33d23a3c8
https://research.vumc.nl/en/publications/49fb3f0b-f269-4eb7-9697-c229dc8f080d
https://research.vumc.nl/en/publications/49fb3f0b-f269-4eb7-9697-c229dc8f080d
Autor:
Amy Harlow, Gerrit Jan Schuurhuis, Fedor Denkers, Corine J. Hess, Angèle Kelder, N. Feller, Pauline A. Merle, Gert J. Ossenkoppele, Quinten Waisfisz, Johannes Berkhof, Michael Heinrich
Publikováno v:
Hess, C J, Feller, N, Denkers, F, Kelder, A, Merle, PA, Heinrich, M C, Harlow, A, Berkhof, J, Ossenkoppele, G J, Waisfisz, Q & Schuurhuis, G J 2009, ' Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia ', Haematologica, vol. 94, no. 1, pp. 46-53 . https://doi.org/10.3324/haematol.13110
Haematologica, 94(1), 46-53. Ferrata Storti Foundation
Haematologica, 94(1), 46-53. Ferrata Storti Foundation
Background About 70–80 percent of patients with acute myeloid leukemia enter complete remission, but at least half of these patients who achieve remission go on to relapse. Improved treatment is likely to come from increasing the time to relapse, e
Autor:
Sonja Zweegman, Gert J. Ossenkoppele, Pauline A. Merle, A H Loonen, Marisa Westers, Pino J. Poddighe, Hans Wessels, Shama L. Bhola, Marielle J. Wondergem
Publikováno v:
Poddighe, P J, Wessels, H, Merle, P, Westers, T M, Bhola, S L, Loonen, A, Zweegman, S, Ossenkoppele, G J & Wondergem, M J 2014, ' Genomic amplification of MYC as double minutes in a patient with APL-like leukemia ', Molecular cytogenetics, vol. 7, 67 . https://doi.org/10.1186/s13039-014-0067-6
Molecular cytogenetics, 7:67. BioMed Central
Molecular Cytogenetics
Molecular cytogenetics, 7:67. BioMed Central
Molecular Cytogenetics
Background Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) characterized by a PML-RARA fusion due to a translocation t(15;17). Its sensitivity to treatment with all-trans retinoic acid (ATRA), which causes differentiat
Autor:
Pauline A. Merle, Gerrit-Jan Schuurhuis, Henk W. Berendse, Gert J. Ossenkoppele, Jeroen Janssen
Publikováno v:
American Journal of Hematology, 84(10), 679-682. Wiley-Liss Inc.
Janssen, J J W M, Berendse, H W, Schuurhuis, G J, Merle, P A & Ossenkoppele, G J 2009, ' A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment ', American Journal of Hematology, vol. 84, no. 10, pp. 679-682 . https://doi.org/10.1002/ajh.21489
Janssen, J J W M, Berendse, H W, Schuurhuis, G J, Merle, P A & Ossenkoppele, G J 2009, ' A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment ', American Journal of Hematology, vol. 84, no. 10, pp. 679-682 . https://doi.org/10.1002/ajh.21489
A 51-year-old male was diagnosed with chronic phase chronic myeloid leukemia (CML) in May 2005. His Sokal score at diagnosis was 0.95 and his Euro score was 1,363 (both intermediate risk). Cytogenetic examination showed 46XY, t(9;22)(q34;q11.2) in al
Autor:
Fedor Denkers, Gerrit Jan Schuurhuis, Nicole Feller, Pauline A. Merle, Quinten Waisfisz, Corine J. Hess, Gert J. Ossenkoppele
Publikováno v:
Blood, 106(11), 162A-162A. American Society of Hematology
Hess, CJ, Feller, N, Denkers, F, Merle, PA, Ossenkoppele, GJ, Waisfisz, Q & Schuurhuis, GJ 2005, ' Immunophenotypical minimal residual disease as a short term endpoint for monitoring effects of targeted inhibitors in acute myeloid leukemia. ', Blood, vol. 106, no. 11, pp. 162A-162A . https://doi.org/10.1182/blood.V106.11.545.545
Hess, CJ, Feller, N, Denkers, F, Merle, PA, Ossenkoppele, GJ, Waisfisz, Q & Schuurhuis, GJ 2005, ' Immunophenotypical minimal residual disease as a short term endpoint for monitoring effects of targeted inhibitors in acute myeloid leukemia. ', Blood, vol. 106, no. 11, pp. 162A-162A . https://doi.org/10.1182/blood.V106.11.545.545
At present, a large number of clinical trails make use of inhibitors that target leukemia specific defects, such as BCR-ABL, c-kit mutations or tandem duplications in the FLT3 gene (FLT3-ITD). Irrespective of their target, these studies all share the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::639599267d06f28498153f31cf5004eb
https://research.vumc.nl/en/publications/ff587fdc-0ddb-450c-96f5-3f6169307452
https://research.vumc.nl/en/publications/ff587fdc-0ddb-450c-96f5-3f6169307452